![]() | |
Clinical data | |
---|---|
Trade names | Zostex, Mevir, Brivir, many others |
Other names | BVDU |
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 30% |
Protein binding | >95% |
Metabolism | Thymidine phosphorylase |
Metabolites | Bromovinyluracil |
Elimination half-life | 16 hours |
Excretion | 65% renal (mainly metabolites), 20% faeces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C11H13BrN2O5 |
Molar mass | 333.138 g·mol−1 |
3D model (JSmol) | |
Specific rotation | +9°±1° |
Density | 1.86 g/cm3 |
Melting point | 165 to 166 °C (329 to 331 °F) (decomposes) |
| |
| |
![]() ![]() |
Brivudine (trade names Zostex, Mevir, Brivir, among others) is an antiviral drug used in the treatment of herpes zoster ("shingles"). Like other antivirals, it acts by inhibiting replication of the target virus.